Indeed, FGF-21 inhibitors, FGF-19 analogs and antiobesity agents like aramchol, orlistat or gut microbiome modulators are other therapeutic options for NAFLD treatment that ameliorate liver damage, insulin sensitivity, body weight and the activation of Kupffer cells (105). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.